Purpose: To investigate the pain relief effect and safety of percutaneous radiofrequency ablation (RFA) with a multitined electrode combined with cement injection in patients with painful metastatic bone tumors. Materials and methods: Sixteen patients with 34 osteolytic metastatic lesions were treated with RFA including 4 males and 12 females (age range 54-84). Thirteen patients with spinal metastases received additional cement injection. Medical imaging, a visual analog scale (VAS) and the EORTC QLQ-C30 were performed to evaluate the metastatic lesion, pain and quality of life, respectively, before and after RFA and at follow-ups. Results: The RFA and/or vertebroplasty with cement injection were successful in all patients (100%). Except for one patient who had cement leakage, no intraprocedural complications occurred. After RFA, severe refractory pain was greatly relieved in all patients, with pretreatment VAS score of 8.1 ± 1.4 significantly reduced to 5.5 ± 1.1 at 24 h, 2.8 ± 0.6 at 1 week and 1.4 ± 0.8 at 6 months (P < 0.01). The EORTC QLQ-C30 scale at 1 month demonstrated significant improvement (P < 0.05) in the physical (P = 0.03) and emotion function (P = 0.003), global health status (P = 0.002), pain (P = 0.001) and insomnia (P = 0.002). The analgesics were reduced after the procedure and stopped 2 months later in all patients, with greatly improved quality of life and no apparent pain. Followed up for 6-12 months, all patients remained alive with no recurrence of pain. Palliative pain relief and safety of percutaneous radiofrequency ablation combined with cement injection for bone metastasis Conclusion: RFA with or without bone cement is safe and effective in the palliative treatment of pain caused by metastatic bone tumors.
Introduction
The skeleton is more commonly affected by metastatic than primary carcinomas and is the third commonest site of metastases (1) (2) (3) (4) (5) (6) .
Clinically, skeleton metastases can produce severe pain, pathological fracture, disruption of bone marrow hematopoiesis or problems with local neuromuscular function (7) . Anatomically, 70% of cases with metastases involve the axial skeleton, and skeleton metastasis beyond the knee or elbow is rare (8) . The majority (up to 70%) of patients with documented malignant neoplasms develop osteolytic metastases (9) , resulting in severe intractable pain limiting mobility and decreasing quality of life (QOL). Traditionally, conservative approaches have been applied to treat nonoperable painful bone metastases using radiotherapy, chemotherapy and analgesics (10) . With recent technical development, micro-invasive methods have been introduced for painful bone-metastatic lesions including ethanol (11) , laser (12) , cryoablation (13) and radiofrequency ablation (RFA). RFA was first reported by Rosenthal et al. in the musculoskeletal system for treating osteoid osteoma in 1992 (14, 15) , and since then, successful ablation for painful osteolytic metastases has been reported more frequently (16) . Palliative therapy for patients with osteolytic bone metastases poses a great challenge, demanding a comprehensive multidisciplinary approach. Percutaneous cement injection provides pain relief and bone strengthening in patients with malignant neoplasms or metastases of bone (17) , and since the cement is highly resistant to compression forces, it is suitable for fractures involving weight-bearing bones like vertebral body and acetabulum and in any bones subject to compression forces. This study was to investigate the safety and palliative pain relief effect of percutaneous RFA with a multitined electrode of 13 hooks with or without combined cement injection in patients with metastatic bone tumors.
Materials and methods

Subjects
This study was approved by the ethics committee of our hospital, and all the patients signed informed consent for the study. Patients enrolled in this study were known to have a primary malignant tumor with metastatic osseous disease. The enrollment criteria included osteolytic metastatic lesions, pain refractory to analgesic medications, over 18 years of age, the ability to give written informed consent and a life expectance greater than 1 month. Patients with osteoblastic metastatic lesions were not included because these lesions would preclude needle introduction and/or ablation electrode deployment. Other exclusion criteria included patients with platelet counts less than 50 000, any local or systemic infection, metastatic lesion located within 1 cm of the spinal cord, aorta, inferior vena cava, bowel and bladder. Between February 2011 and March 2013, 16 patients with 34 osteolytic metastatic lesions were enrolled and treated in our hospital with RFA including 4 males and 12 females (age range 54-84, mean 66.8). The metastases all occurred after the original carcinomas had been completely surgically resected. The primary malignances included lung cancers in nine patients, hepatic carcinomas in three, breast cancers in two, rectal carcinoma in one and malignant lymphoma in the remaining one (Table 1) . Among the 16 patients, 14 had vertebral metastases with 30 vertebral bodies involved including nine patients with thoracic (19 vertebral bodies involved), four with lumber (9 vertebral bodies) and one with sacral vertebral metastases (2 vertebral bodies). The rest two patients had scapular metastasis in one and sternal and rib metastases in the remaining one. No compression fracture occurred in these patients, but all patients had severe local pain refractory to medications and relied on sauteragyl for pain relief.
Evaluation
Medical imaging was performed in all patients including computed tomography (CT), magnetic resonance imaging (MRI) and/or emission computed tomography (ECT) before RFA for correct diagnosis. Visual analog scale (VAS) was used to assess the pain in each patient on a scale from 0-10 (0 = no pain, 10 = the worse pain ever imagined). The QOL of all patients were measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) which is a widely used cancerspecific instrument (18) . This instrument includes 30 questions with 15 domains consisting of 5 function scales, 8 symptom scales, a global quality of life scale and a finance scale. For the Chinese version of this scale, low scores indicate better health-related QOL. These two scales were evaluated and recorded before and after the procedure and at every follow-up.
RFA procedure
The RFA procedure was performed under local anesthesia and conscious sedation using a RFA-I type multipolar cancer ablation system (Beijing Bolai, Beijing, China) with a 13-hooked electrode which has a diameter of 4 cm when fully opened (Fig. 1A and B) . This system is capable of producing a maximal output of 300 W, 330 KHz and 110°C and can be used for ablation of multiple carcinomas and other diseases like hypersplenism. One single ablation can create a necrosis area of 5-6 cm in diameter when the electrode is fully opened. Ablation can also be performed with the clustered needle half opened to create a smaller ablation area, but the necrosis area is 1.5-2 cm in diameter near the tip of each hook. Imaging guidance was provided by the Allura Xper FD-20 flat detectro (Philips Medical System, Best, The Netherlands) with CT scanning function. The tip of the electrode was set at a temperature of 95°C, and the ablation lasted for 5-10 minutes. The electrode tip was accurately inserted into the center of the metastatic lesion and was adjusted at the angle and direction for multiple ablations in irregular lesions. Thirteen patients with vertebral metastases had additional vertebroplasty with polymethylmethacrylate radio-opaque bone cement injection (Fig. 1F ). Cardiac and respiratory parameters were monitored during the whole procedure.
Patient assessment and follow-up
Intraprocedural complications were evaluated immediately after the procedure and at follow-ups. Within 1 week after treatment, patients had X-ray, CT or MRI examinations, which were compared before the treatment. Pain was evaluated with the VAS at 24, 48, 74 h, 1 week, 1 month, 2, 3 and 6 months and compared with before treatment. The QOL was assessed with the EORTC QLQ-C30 scale at 1 month after treatment and compared with before treatment.
Statistical analysis
The SPSS 19 software (IBM, Chicago, IL, USA) was used for statistical analysis. Continuous data were expressed as mean ± standard deviation (SD). Students' t-test was used to compare the difference between different groups, with the significant P value set at <0.05.
Results
All patients had successful RFA (100%), and 13 patients with spinal metastases also had successful vertebroplasty (Fig. 1 ). For the patient who had right scapular metastatic lesion, RFA was performed after arterial infusion of antitumor agents through the right subclavian artery and endovascular embolization of the tumor supplying artery (Fig. 2) . Cement leakage (6.25%) occurred in one patient who had metastatic destruction of the posterior cortex of one vertebral body, and the leaked cement compressed nerve roots causing moderate pain which was resolved 2 days later after surgical removal of the leaked cement. No other complications occurred during the procedure.
After the procedure, the severe refractory pain was greatly relieved in all patients. The VAS score was 8.1 ± 1.4 (range 5.0-10) prior to treatment but was significantly reduced to 5.5 ± 1.1 (range 3.4-7.8) at 24 h, 5.1 ± 1.0 (range 3.0-7.0) at 48 h and 4.8 ± 0.9 (range 2.9-6.8) at 72 h after treatment. Followed up for 6 months, T, thoracic vertebra; L, lumbar vertebra; S, sacral vertebra; RFA, radiofrequency ablation; PVP, percutaneous vertebroplasty; AE, arterial embolization; m, month. the pain continued to relieve, with the VAS score of 2.8 ± 0.6 (range 1.8-3.6) at 1 week but 1.4 ± 0.8 (range 0-2.5) at 6 months post RFA (P < 0.01) ( Table 2 and Fig. 3) . A significant (P < 0.05) difference existed at every time point after compared with before the procedure. Thirteen patients received additional cement injection while the rest three did not. Evaluation of patients with (13 patients) or without (3 patients) cement injection revealed no significant (P > 0.05) difference in the VAS scores before and after the procedure and at follow-ups.
Evaluation of the EORTC QLQ-C30 scale at 1 month compared with before the procedure also demonstrated significant improvement (P < 0.05, Table 3 and Fig. 3 ) in the physical function (P = 0.03), emotion function (P = 0.003), global health status (P = 0.002), pain (P = 0.001) and insomnia (P = 0.002). Twenty-four hours after the procedure, the analgesic doses were reduced in all patients, and the dependence on analgesics was decreased to different extents within 1 week. Two months later, all patients had greatly improved QOL and stopped the analgesic because of no apparent pain to affect life and sleep.
Imaging examinations showed no enhancement in the necrosis area in enhanced CT. For patients with RFA and vertebroplasty, the necrosis area caused by osteolytic metastasis and RFA was filled by well-distributed cement. No soft tissue damage or edema and the spinal cord were not compressed by the injected cement. Followed up for 6-12 months (mean 8.4 months), all patients remained alive with no recurrence of pain. 
Discussion
About 30-50% of patients with cancer will experience pain, and 75-90% of advanced cancers create substantial, life-changing pain (19) . Pain is the commonest symptom of primary and metastatic bone cancer (19) . Bone cancer-induced pain is dull and constant, elevates with time and is worsened by use of involved portions of the skeleton. Intermittent episodes of extreme pain takes place spontaneously or after weight bearing or movement of the affected limb (20, 21) . Management of pain in patients with terminally ill diseases, bone metastases in particular, can be challenging, and conventional treatment options for pain control comprise radiation and/or chemotherapy, surgery and use of opioid and other analgesics (22) . In spite of these approaches, the QOL for these patients is very poor due to the intolerable pain. Bone cancer pain is induced by bone destruction which is accomplished by osteoclasts (23) , the body's major bone-reabsorbing cells. Moreover, the pain caused by vertebral and extravertebral bone tumors may result from mechanical stress on the periosteal nociceptor and a cascade of biohumoral factors and cytokines created by the tumor cells themselves (24) . RFA uses a high-frequency alternating current which is passed from the electrode needle into the adjacent tissues, leading to frictional heating and tissue necrosis. RFA can cause necrosis of metastatic tumor cells producing nervestimulating cytokines, destroy adjacent sensory nerve fibers involving sense and transmission of pain, stop bone destruction, inhibit osteoclast activity to cause pain and stop further release of different cytokines and biohumoral factors (19, 25, 26) . Callstrom et al. (22) investigated the feasibility of percutaneous imaging-guided RFA in patients with painful metastases of bone and reported up to 84% pain relief and improved QOL with reduced interference from pain in daily life 4 weeks after RFA. Goetz et al. (27) reported significant pain relief in 41 of 43 bone-metastatic patients treated with RFA 6 months later. These studies demonstrated definite effect of pain relief of RFA.
Cement injection for vertebroplasty can stabilize the skeletal segment and consequently prevent periosteal deformation and pain (28) . RFA and cement injection may combine to relieve pain and improve QOL. One advantage of RFA before cement injection is a greater control over cement distribution which may be useful in posteriorly located lesions (16) . On the other hand, RFA can form an ablation-shell barrier preventing live tumor cell spread caused by cement injection which may result in tumor cell displacement and spread. RFA may also cause thrombosis of the intravertebral venous plexus, subsequently decreasing the risk of cement leakage. Lane et al. (16) reported pain relief in some patients treated with combined RFA and vertebroplasty even if the entire bone-metastatic lesion was not ablated. Gronemeyer et al. (29) combined RFA and vertebroplasty into a single procedure for treating unresectable spine metastases in four patients and reported substantial decrease in pain and disability in the patients. In our study, 13 patients had cement injection of the metastatic vertebral bodies following successful RFA, and all patients stopped taking analgesics 2 months after the procedure with improved QOL. Evaluation of VAS in patients with or without cement injection revealed no significant difference (P > 0.05) after the procedure and at follow-ups, indicating that cement injection did not play a significant role in relieving pain.
RFA combined with cement inject may cause injury to adjacent nerves, blood vessels, skin, muscles and arthrodial cartilage. The reported complication rate for percutaneous vertebroplasty is low (below 10%), but cement leakage can occur as high as 81% as verified by CT (30) . In our study, cement leakage occurred in one patient. Barragan-Campos et al. (31) studied 159 percutaneous vertebroplasty procedures to treat 304 vertebral bodies and found 423 incidences of cement leakage, though only two of the leakages caused systemic complications (pulmonary embolism caused by cement migration through the vena cava). Nakatsuka et al. (32) reported serious complications of incomplete hemiplegia and radiculopathy in four patients after treating 17 spinal cases using an internally cooled straight electrode for RFA combined with vertebroplasty under CT fluoroscopy guidance. All these complications occurred in patients in whom the tumor had invaded the posterior cortex and a pedicle of the vertebral body. In the absence of direct compressive symptoms, destruction of the posterior vertebral body cortex or epidural extension of tumor has been described as a relative contraindication to vertebroplasty because of possible cement leakage (33) . In patients without invasion of the posterior cortex and the pedicles, the combined procedure would be safe enough. Shimony et al. (33) reported successful vertebroplasty in patients with metastasis-related compression fracture but without posterior cortical disruption, and follow-up phone calls showed good pain relief in 82% of patients and no severe complications.
Goetz et al. (27) treated 43 patients of painful bone metastases using RFA and reported two-point drop in worst pain in 95% of patients following RFA. The relief of pain was achieved quickly with 41% achieving at least a two-point drop in pain by week 1 and 59% achieving so by week 4. Significant decreases in opioid requirements were also achieved at weeks 8 and 12 in the study by Goetz et al. (27) . In our study, significant improvement in the pain and QOL was demonstrated by using the VAS and the EORTC QLQ-C30 scales which can accurately evaluate the refractory pain and QOL of the patients with bone metastases. The mean drop in the pain was 3.3 points at 72 h, 5.3 at week 1, 5.7 at month 1, and 6.7 at month 6 when assessed with the VAS. In evaluating the QOL at 1 month post RFA compared with before RFA, the physical function improved 2.09 points, the emotional function 2.1, the global health status score 1.83 and the appetite loss 1.91 in the mean value.
Our study has some limitations. This study was designed to detect the palliative pain relief effect and safety of the RFA procedure with or without combined cement injection. A limited number of patients, lack of a big controlled group, and short-term follow-up were limitations of this study. The patients were only followed for up to 12 months after the procedure, and long-term follow-up should be performed to determine the recurrence rate and long-term survival. Since this patient population was terminally ill and had malignant metastases rather than isolated diseases, it was really difficult to perform longer follow-up. Further studies involving many centers are necessary to improve the effect of RFA, expand the application scope of RFA for tumors or metastases and decrease possible complications.
In conclusion, radiofrequency ablation with or without combined cement injection is safe and effective in the palliative treatment of patients with painful metastatic bone tumors, including skeleton metastases.
